Paris - Delayed Quote EUR
GeNeuro SA (GNRO.PA)
At close: October 18 at 4:10 PM GMT+2
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Operating Expense
14,357.3000
14,357.3000
11,818.4000
6,832.9000
7,459.1000
--
Operating Income
-14,357.3000
-14,357.3000
-11,818.4000
-6,832.9000
-7,459.1000
--
Net Non Operating Interest Income Expense
-876.7000
-876.7000
-261.7000
-38.7000
-1,441.5000
--
Pretax Income
-14,752.8000
-14,752.8000
-12,197.7000
-6,817.7000
-8,962.3000
--
Tax Provision
4.2000
4.2000
2.1000
--
--
--
Net Income Common Stockholders
-14,757.0000
-14,757.0000
-12,199.8000
-6,817.7000
-8,962.3000
--
Diluted NI Available to Com Stockholders
-14,757.0000
-14,757.0000
-12,199.8000
-6,817.7000
-8,962.3000
--
Basic EPS
-0.54
-0.59
-0.51
-0.32
-0.45
--
Diluted EPS
-0.54
-0.59
-0.51
-0.32
-0.45
--
Basic Average Shares
24,858.3100
25,011.8640
23,898.3170
21,280.0090
19,969.2930
--
Diluted Average Shares
24,858.3100
25,011.8640
23,898.3170
21,727.5000
19,969.2930
--
Total Operating Income as Reported
-14,357.3000
-14,357.3000
-11,229.2000
-6,365.7000
-7,459.1000
--
Rent Expense Supplemental
36.1000
36.1000
39.3000
34.1000
37.4000
--
Total Expenses
14,357.3000
14,357.3000
11,818.4000
6,832.9000
7,459.1000
--
Net Income from Continuing & Discontinued Operation
-14,757.0000
-14,757.0000
-12,199.8000
-6,817.7000
-8,962.3000
--
Normalized Income
-15,495.3135
-15,495.3135
-12,199.8000
-6,817.7000
-8,962.3000
--
Interest Income
75.9000
75.9000
7.6000
1.9000
3.1000
--
Interest Expense
--
--
--
--
72.3000
441.9000
Net Interest Income
-876.7000
-876.7000
-261.7000
-38.7000
-1,441.5000
--
EBIT
-14,357.3000
-14,357.3000
-11,818.4000
-6,832.9000
-8,890.0000
--
EBITDA
-14,063.5000
-14,063.5000
-11,530.0000
-6,532.8000
-8,528.2000
--
Reconciled Depreciation
293.8000
293.8000
288.4000
300.1000
361.8000
--
Net Income from Continuing Operation Net Minority Interest
-14,757.0000
-14,757.0000
-12,199.8000
-6,817.7000
-8,962.3000
--
Total Unusual Items Excluding Goodwill
806.9000
806.9000
--
--
--
--
Total Unusual Items
806.9000
806.9000
--
--
--
--
Normalized EBITDA
-14,870.4000
-14,870.4000
-11,530.0000
-6,532.8000
-8,528.2000
--
Tax Rate for Calcs
0.0001
0.0001
0.0001
--
--
--
Tax Effect of Unusual Items
68.5865
68.5865
--
--
--
--
12/31/2019 - 4/15/2016
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
AELIS.PA Aelis Farma SA
3.6000
-8.63%
KDEV.ST Karolinska Development AB (publ)
1.2760
+4.25%
BPTSY Biophytis S.A.
3.4200
+0.29%
ALGEN.PA genOway Société anonyme
3.7100
-0.27%
ALTME.PA TME Pharma N.V.
0.1298
+1.88%
ALBPS.PA Biophytis S.A.
0.3598
+2.80%
HPHA.DE Heidelberg Pharma AG
2.6700
+4.71%
VICO.ST Vicore Pharma Holding AB (publ)
8.62
-6.00%
ALCLS.PA Cellectis S.A.
1.8360
+0.44%
TNG.PA Transgene SA
1.0040
-3.65%